Enveric Biosciences (ENVB) AI Stock Analysis

• Market Cap: $2.95M
• Dividend Yield: N/A
• Average Volume (3M): 781.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: N/A
• EPS Growth: 79.45%
• Country: US
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -11.64
• Shares Outstanding: 518,297
• 10 Day Avg. Volume: 899,153
• 30 Day Avg. Volume: 781,309
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.70
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.35
• Enterprise Value/Market Cap: 0.10
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.19
• Enterprise Value/Ebitda: -0.03
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 24 Underperform
• Price Target: ―

Enveric Biosciences faces significant financial difficulties, with no revenue and ongoing losses, which heavily impacts its overall score. The technical indicators suggest a bearish trend, adding to the negative outlook. The valuation component is challenging due to negative earnings, making the stock less attractive. Overall, the company's financial instability is the most significant factor affecting its stock score.

Positive Factors

Pipeline Advancement

The successful completion of toxicology studies for EB-003 marks a significant milestone, advancing the drug closer to clinical trials. This progress strengthens Enveric's pipeline, potentially leading to future revenue through commercialization or partnerships.

No Debt

Enveric's absence of debt reduces financial risk, offering a buffer against financial instability. This positions the company to potentially leverage future financing opportunities without the burden of existing debt obligations.

Intellectual Property

Receiving a notice of allowance for EVM401 strengthens Enveric's intellectual property portfolio. This enhances the company's competitive edge and potential for future licensing deals, which could lead to revenue generation.

Negative Factors

No Revenue

The lack of revenue generation since 2020 highlights a critical challenge for Enveric. Without income, the company remains reliant on external financing, which may not be sustainable long-term, threatening its financial viability.

Negative Cash Flow

Consistently negative operating cash flow indicates Enveric's inability to generate cash from its operations. This ongoing cash burn could limit the company's ability to invest in R&D and sustain operations without additional financing.

Ongoing Losses

Persistent losses reflect operational challenges and unprofitability, which can erode shareholder equity and limit strategic flexibility. This ongoing financial strain poses a risk to Enveric's long-term sustainability and growth prospects.

Enveric Biosciences Business Overview & Revenue Model

Company Description

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

How the Company Makes Money

Enveric Biosciences primarily makes money through the development and potential commercialization of its proprietary drug candidates. The company invests heavily in research and development to advance its therapeutic pipeline. Revenue is expected to be generated through licensing agreements, partnerships with pharmaceutical companies, and potential product sales following successful clinical trials and regulatory approvals. As Enveric's drug candidates move closer to market readiness, collaborations with established industry players may provide additional financial support and revenue opportunities.

Enveric Biosciences Financial Statement Overview

Summary

Enveric Biosciences is facing significant financial challenges with no revenue generation, ongoing operational losses, and negative cash flows. While the absence of debt reduces financial risk, the company's continued reliance on financing activities to cover cash flow deficits is unsustainable in the long term.

Income Statement

Enveric Biosciences has not generated any revenue since 2020, and the company's net income remains negative, indicating persistent losses. The consistent negative EBIT and EBITDA margins point to ongoing operational challenges and unprofitability.

Balance Sheet

The company has a moderate level of stockholders' equity relative to its total assets, but the lack of debt provides some financial stability. However, the continuous erosion of equity due to ongoing losses is concerning for long-term sustainability.

Cash Flow

Operating cash flow is consistently negative, reflecting the company's inability to generate cash from operations. This is partially offset by financing activities, but free cash flow remains negative, indicating cash burn issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-243.86K	-337.49K	-408.03K	-435.20K	-681.61K	-120.87K
EBITDA	-9.48M	-9.23M	-16.85M	-19.52M	-55.74M	-6.30M
Net Income	-9.73M	-9.57M	―	-18.50M	-48.98M	-6.86M
Balance Sheet
Total Assets	4.36M	3.08M	4.30M	19.55M	26.72M	4.10M
Cash, Cash Equivalents and Short-Term Investments	3.76M	2.24M	2.29M	17.72M	17.36M	1.58M
Total Debt	0.00	0.00	0.00	63.82K	176.30K	0.00
Total Liabilities	905.88K	1.49M	2.34M	4.00M	4.41M	681.25K
Stockholders Equity	3.46M	1.59M	1.96M	14.67M	22.31M	3.42M
Cash Flow
Free Cash Flow	-7.67M	-7.73M	-14.10M	-17.73M	-12.32M	-3.93M
Operating Cash Flow	-7.67M	-7.73M	-14.09M	-17.15M	-11.46M	-3.89M
Investing Cash Flow	0.00	0.00	11.67K	-584.16K	2.19M	-44.14K
Financing Cash Flow	8.35M	7.67M	-1.34M	18.18M	24.90M	5.53M

Enveric Biosciences Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENVB, the sentiment is Negative. The current price of 5.82 is below the 20-day moving average (MA) of 5.89, below the 50-day MA of 7.08, and below the 200-day MA of 13.66, indicating a bearish trend. The MACD of -0.46 indicates Negative momentum. The RSI at 43.21 is Neutral, neither overbought nor oversold. The STOCH value of 52.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENVB.

Enveric Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BDRX	45 Neutral	$3.35M	-0.08	-60.37%	―	-100.00%	86.75%
GTBP	34 Underperform	$8.04M	―	-356.99%	―	―	54.62%
ARTL	34 Underperform	$2.13M	-0.10	-436.14%	―	―	-22.52%
SLRX	30 Underperform	$3.37M	-0.07	-139.55%	―	―	68.08%
INDP	27 Underperform	$3.14M	-0.08	-317.98%	―	―	34.57%
ENVB	24 Underperform	$2.95M	-0.04	-262.78%	―	―	79.45%

Enveric Biosciences Corporate Events

Enveric Biosciences Prepares Presentation for February 2025

Enveric Biosciences, Inc. announced that it has prepared presentation materials, which management intends to release on its website around February 26, 2025. These materials may be used in future presentations to various stakeholders, including investors and business partners, highlighting the company’s ongoing efforts to engage with its audience and provide updates on its business activities.